John Jenco’s Post

Sharing this article about AI Integration In Drug Manufacturing by Josefine Sommer, Christopher Fanelli, Eva von Mühlenen, Michelle Gandolfo, and Julea Lipiz, Sidley Austin LLP. In the pharmaceutical industry, the integration of artificial intelligence (AI) and machine learning (ML) into drug manufacturing processes is redefining how drugs are manufactured and controlled for quality. Data integrity and security are top considerations when manufacturers adopt the use of AI applications.

Strategic roadmapping for AI in the pharmaceutical industry can revolutionize drug discovery, leading to a profound impact on both business outcomes and patient care. A pharmaceutical company experienced a 40% reduction in drug discovery times by implementing an AI roadmap, showcasing the transformative power of AI in accelerating the development of new treatments. This case study highlights the critical role of innovations, tech transfer, patent searching, patent drafting, and technical writing in driving AI-powered advancements in the field. The actionable insight from this case study is that a comprehensive and well-aligned AI strategy can unlock significant value for pharmaceutical companies by streamlining drug discovery and development processes. An actionable takeaway for industry leaders is to prioritize the integration of AI technologies and invest in the necessary talent and infrastructure to harness the full potential of AI in drug discovery. https://lnkd.in/gAJx7bET

Strategic roadmapping for AI in the pharmaceutical industry can revolutionize drug discovery, leading to a profound impact on both business outcomes and patient care. A pharmaceutical company experienced a 40% reduction in drug discovery times by implementing an AI roadmap, showcasing the transformative power of AI in accelerating the development of new treatments. This case study highlights the critical role of innovations, tech transfer, patent searching, patent drafting, and technical writing in driving AI-powered advancements in the field. The actionable insight from this case study is that a comprehensive and well-aligned AI strategy can unlock significant value for pharmaceutical companies by streamlining drug discovery and development processes. An actionable takeaway for industry leaders is to prioritize the integration of AI technologies and invest in the necessary talent and infrastructure to harness the full potential of AI in drug discovery. https://lnkd.in/gAJx7bET

FDA plans to release AI drug development guidelines. Key takeaways: The FDA is set to revolutionize drug development with its forthcoming draft guidance on utilizing AI/ML, marking a pivotal moment in regulatory history. The exponential rise in AI-driven submissions, from just one in 2016 to a staggering 128 by 2021, underscores the pharmaceutical industry's rapid adoption of cutting-edge technology. AI's multifaceted role spans every phase of drug development, promising to streamline processes and enhance outcomes. With over 800 comments received, FDA's commitment to incorporating stakeholder feedback ensures a collaborative approach in shaping robust regulatory frameworks for AI integration. Alongside the guidance, FDA's initiatives to establish best practices and uniform terminologies signal a proactive stance towards harnessing AI's full potential while fostering transparency and global harmonization.

Strategic roadmapping for AI in the pharmaceutical industry can revolutionize drug discovery, leading to a profound impact on both business outcomes and patient care. A pharmaceutical company experienced a 40% reduction in drug discovery times by implementing an AI roadmap, showcasing the transformative power of AI in accelerating the development of new treatments. This case study highlights the critical role of innovations, tech transfer, patent searching, patent drafting, and technical writing in driving AI-powered advancements in the field. The actionable insight from this case study is that a comprehensive and well-aligned AI strategy can unlock significant value for pharmaceutical companies by streamlining drug discovery and development processes. An actionable takeaway for industry leaders is to prioritize the integration of AI technologies and invest in the necessary talent and infrastructure to harness the full potential of AI in drug discovery. https://lnkd.in/gAJx7bET

Strategic roadmapping for AI in the pharmaceutical industry can revolutionize drug discovery, leading to a profound impact on both business outcomes and patient care. A pharmaceutical company experienced a 40% reduction in drug discovery times by implementing an AI roadmap, showcasing the transformative power of AI in accelerating the development of new treatments. This case study highlights the critical role of innovations, tech transfer, patent searching, patent drafting, and technical writing in driving AI-powered advancements in the field. The actionable insight from this case study is that a comprehensive and well-aligned AI strategy can unlock significant value for pharmaceutical companies by streamlining drug discovery and development processes. An actionable takeaway for industry leaders is to prioritize the integration of AI technologies and invest in the necessary talent and infrastructure to harness the full potential of AI in drug discovery. https://lnkd.in/gAJx7bET

This could be a game changer for the Pharma industry. What does anyone else think? Pro’s Con’s? “The head of Google DeepMind believes its drug discovery spinout will halve the time taken to find new medicines, attracting the attention of the world’s biggest pharmaceutical companies which are looking to artificial intelligence to revolutionise the lengthy process. Speaking to the Financial Times Demis Hassabis, who co-founded Google’s AI unit and also leads the drugs offshoot Isomorphic Labs, said the goal was to reduce the discovery stage — when potential drugs are identified before clinical trials — from the average of five years to two. “I think that would be success for us and be very meaningful,” he said. Hassabis stated the goal days after announcing Isomorphic Lab’s first two pharmaceutical partnerships with Eli Lilly and Novartis which came to a combined value of up to $3bn, in deals set to transform the finances of the unprofitable group. Isomorphic Labs uses an AI platform to predict biochemical structures, which aids the creation of new drugs by recommending which potential compounds will have the desired impact in the body. Including clinical trials, it often takes up to a decade to discover and develop a new drug, costing on average about $2.7bn, according to research by the Tufts Center for the Study of Drug Development. #drugdiscovery #pharmaceutical #pharma #artificialintelligence #ai #clinicaltrials

"Accelerated drug discovery. More efficient clinical trials. Quicker regulatory approvals. Ultratargeted marketing and medical materials generated in-house. #GenerativeAI is transforming nearly all aspects of the #pharmaceutical industry, revamping the way companies operate and potentially unlocking billions of dollars in value. The McKinsey & Company Global Institute (MGI) has estimated that the technology could generate $60 billion to $110 billion a year in economic value [..]." #teambayer #healthforall #digitization #ai https://lnkd.in/dBSmhJ9j

Accelerated drug discovery. More efficient clinical trials. Quicker regulatory approvals. Ultratargeted marketing materials generated in-house. Generative AI is transforming nearly all aspects of the pharmaceutical industry, revamping the way companies operate and potentially unlocking billions of dollars in value. The McKinsey Global Institute (MGI) has estimated that the technology could generate $60 billion to $110 billion a year in economic value for the pharma and medical-product industries, largely because it can boost productivity by accelerating the process of identifying compounds for possible new drugs, speeding their development and approval, and improving the way they are marketed. #pharma #lifesciences #researchanddevelopment #medtech #healthtech #clinicaltrials #regulatory #marketaccess